Venclexta (venetoclax) — Medica
Mantle Cell Lymphoma
Initial criteria
- age ≥ 18 years
- EITHER tried at least one systemic regimen OR (has TP53 mutation AND used as induction therapy in combination with Brukinsa (zanubrutinib) and Gazyva (obinutuzumab))
Approval duration
1 year